BioTime Warrants to Expire on October 1, 2018
September 21 2018 - 7:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, is advising
the holders of its publicly traded warrants (NYSE American: BTX.WS)
that the warrants will expire and not be exercisable after 5:00
p.m., New York City time, on October 1, 2018 (the “Expiration
Date”).
A warrant holder can obtain information on exercising the
warrants by contacting their broker or American Stock Transfer
& Trust Company, LLC., BioTime’s warrant agent. Brokers are
encouraged to contact the warrant agent to confirm the procedures
for exercising the warrants.
The NYSE has notified BioTime that trading in the warrants on
the NYSE will be suspended after the close of business on September
26, 2018 to ensure all trades in the warrants settle in time to
allow the purchasers of such warrants to exercise the warrants on
or before the Expiration Date.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on degenerative diseases. Its clinical programs are based on two
platform technologies: cell replacement and cell/drug delivery.
With its cell replacement platform, BioTime is producing
new cells and tissues with its proprietary pluripotent cell
technologies. These cells and tissues are developed to replace
those that are either rendered dysfunctional or lost due to
degenerative diseases or injuries. BioTime’s cell/drug delivery
programs are based upon its proprietary HyStem® cell and drug
delivery hydrogel matrix technology. HyStem® was designed, in
part, to provide for the transfer, retention and/or engraftment of
cellular replacement therapies. HyStem® is a unique hydrogel
that has been shown to support cellular attachment and
proliferation in vivo. Current research at leading medical
institutions has shown that HyStem® is compatible with a wide
variety of cells and tissue types including brain, bone, skin,
cartilage, vascular and heart tissues. Due to the unique
cross-linking chemistry, HyStem® hydrogels have the ability to
mix cells, biologics and small molecule drugs and can be injected
or applied as a gel which allows the hydrogel to conform to a
cavity or space. This property of HyStem® hydrogels offers
several distinct advantages over other hydrogels, including the
possibility of combining bioactive materials with the hydrogel at
the point of use. BioTime is also developing
HyStem® for the delivery of therapeutic drugs and cells to
localized areas of the body, including for sustained drug release
in the targeted anatomical sites. BioTime’s lead cell delivery
clinical program is Renevia®, which consists of
HyStem® combined with the patient’s own adipose (fat) derived
tissue or cells. Renevia® met its primary endpoint in an EU
pivotal clinical trial for the treatment of facial lipoatrophy in
HIV patients in 2017. BioTime has submitted
Renevia® for CE Mark approval in the EU. There were no device
related serious adverse events reported to date. BioTime’s lead
cell replacement product candidate is OpRegen®, a retinal pigment
epithelium transplant therapy, which is in a Phase I/IIa
multicenter clinical trial for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. There have been no unexpected serious adverse
events reported to date. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE American: AST)
and OncoCyte Corporation (NYSE American: OCX), and a
private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications,
please click on the following link to join the Company’s email
alert list: http://news.biotime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180921005054/en/
BioTimeDavid Nakasone,
510-871-4188Dnakasone@biotime.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2023 to Aug 2024